-62.0%
ALNY vs MRNA
+945.0%
-1,007.0%
-66.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.7% | +13.1% | -12.4% | +0.1% |
| 7D | -30.7% | +20.6% | -51.3% | -31.4% |
| 30D | -26.7% | +27.1% | -53.9% | -27.9% |
| 3M | -26.4% | +353.4% | -379.8% | -34.5% |
| 6M | -45.9% | +446.3% | -492.2% | -54.3% |
| YTD | -59.5% | +776.2% | -835.7% | -67.8% |
| 1Y | -62.0% | +987.9% | -1,049.9% | -70.1% |
| All | -62.0% | +945.0% | -1,007.0% | -70.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling